

# Exhibit C

Curriculum Vitae---Wenxin Zheng, M.D.

**CURRICULUM VITAE**Wenxin Zheng, MD  
Professor with Tenure[REDACTED]  
July 04, 2014

Wenxin Zheng

**PERSONAL INFORMATION**

Name in Full: Wenxin Zheng  
 Business Address: Department of Pathology  
 The University of Arizona  
 1501 N. Campbell Ave. #5224A  
 Tucson, AZ 85724  
 Business Phone: [REDACTED]  
 Home Address: [REDACTED]  
 Home Phone: [REDACTED]  
 Place of Birth: Shanghai, China  
 Citizenship: United States of America  
 Marital status: [REDACTED]

**EDUCATION**

1976-1977	College study, biology	Department of Biology, Fudan University Shanghai, China
1977-1982	M.D.	Shanghai Medical College Fudan University 138 Yi Xue Yuan Rd, Shanghai, China
1984-1986	Graduate study Gynecology Endocrinology	Graduate School, Fudan University Shanghai, China

Thesis Title: Ovarian premature failure and its potential causes.

Thesis Advisor: Dr. Yao E Yuan, Professor and President of the Hospital of Obstetrics and Gynecology, Shanghai Medical College Fudan University

**CHRONOLOGY OF EMPLOYMENT AND POSTGRADUATE TRAINING**

## Curriculum Vitae---Wenxin Zheng, M.D.

1982-1986	Intern and Resident	Department of Obstetrics and Gynecology Hospital of Obstetrics and Gynecology Shanghai Medical College Fudan University
1986-1989	Post Doctoral Scientist	Department of Obstetrics & Gynecology College of Physicians and Surgeons Columbia University, New York, NY
1989-1991	Associate Research Scientist	Department of Obstetrics & Gynecology College of Physicians and Surgeons Columbia University, New York, NY
1991-1994	Intern and Resident	Department of Pathology The New York Hospital Cornell University Medical College, New York, NY
1994-1995	Chief Resident	Department of Pathology The New York Hospital Cornell University Medical College, New York, NY
1995-1996	Gynecologic Pathology Fellow and Instructor	Department of Pathology Women and Infants' Hospital Brown University, Providence, RI
1996-2000	Assistant Professor of Pathology and Gynecology Attending Pathologist	Department of Pathology University Southern California School of Medicine Women & Children's Hospital, Los Angeles, CA
1998-2000	Associate Director of Molecular Pathology and Immunohistochemical lab	Department of Pathology University Southern California School of Medicine
2000-2005	Associate Professor of Pathology and Gynecology Attending Pathologist	Department of Pathology Yale University School of Medicine Yale - New Haven Hospital, New Haven, CT
2000-2005	Director of Gynecologic Pathology and Gynecologic Pathology Fellowship	Department of Pathology Yale University School of Medicine Yale - New Haven Hospital, New Haven, CT
2005- present	<b>Professor with tenure</b> of Pathology	Departments of Pathology The University of Arizona Medical College
	Attending Pathologist	University Medical Center and University Physicians Healthcare, Tucson, AZ

Curriculum Vitae---Wenxin Zheng, M.D.

2005- present	<b>Professor with tenure</b> of Obstetrics & Gynecology	Departments of Obstetrics & Gynecology The University of Arizona Medical College
2005- present	Director of Gynecologic and Molecular Pathology	Departments of Pathology, Obstet & Gynecol The University of Arizona Medical College University Medical Center, Tucson, AZ
2005- May 08	Chair Professor of Pathology, Gynecology, and Oncology	Department of Pathology, Pathology Center, and Pathology Diagnostic Center, Shanghai Medical College Fudan University Shanghai, China
2008 – present	Co-director	Tissue Acquisition and Cellular/Molecular Analysis Shared Service Arizona Cancer Center

## HONORS AND AWARDS

1979-1981	Honor Students' Award, every semester, Shanghai Medical College Fudan University, China.
1986-1989	WHO supported Fellowship Award.
1996-1997	American Cancer Society Institutional Research Award, University of Southern California
1997-1998	Zumberge Fellow Award, supported by James H. Zumberge Faculty Research and Innovation Fund, University of Southern California
1998-1999	Wright Foundation Research Award, Los Angeles, CA
1998-1999	Rockefeller Foundation China Bridge Institution Scientific Award, New York, NY
2000-2002	California Cancer Research Program Award, Sacramento, CA
2005-2008	Outstanding Principal Investigator Award, Fudan University, Shanghai, China
2006-2010	Better Than Ever Award, Arizona Cancer Center, Tucson, AZ
2008	Asian American Faculty, Staff, & Alumni Association Award, University of Arizona, Tucson, AZ
2012	Top American Pathologist by US News and World Report. <a href="http://health.usnews.com/top-doctors/wenxin-zheng-pathologist-85CC010348">http://health.usnews.com/top-doctors/wenxin-zheng-pathologist-85CC010348</a>
2012	Top Doctor in the field of Pathology by Castle Connolly Medical LTD ( <a href="http://www.castleconnolly.com">www.castleconnolly.com</a> )
2013	John Davis Outstanding Residency Teaching Award, Department of Pathology, University of Arizona, Tucson, AZ
2013	Better Than Ever Award, Arizona Cancer Center, Tucson, AZ
2013	Cancer Center Supporting Grant Award, Arizona Cancer Center, Tucson, AZ
2013	Colleen's Dream Fund award, Tucson, Arizona
2013-2015	Outstanding Oversea Teacher's Award, Department of Education, China
2013	Excellence Teaching Award, College of Medicine, University of Arizona, Tucson, AZ

## BOARD CERTIFICATION AND LICENSURE

Curriculum Vitae---Wenxin Zheng, M.D.

1996           Diplomate of The American Board of Pathology in combined Anatomic Pathology and Clinical Pathology

### **Medical practice licenses in United States**

1995-1998    New York, #200339  
 1996-2002    California, #A61328,  
 2000-2008    Connecticut, # 039113,  
 2005-        Arizona, #34676  
 DEA:         BZ5264457

### **SERVICE**

1993-1995    Reproductive Biology Resource Committee  
               College of American Pathologist (CAP) and American Fertility Society (AFS),  
 1996-        Gynecologic pathology and gynecologic cytology signouts and  
               Weekly gynecology oncology tumor board presentation  
 1997- 2005   Monthly quality control of cytology and biopsy correlations  
 1997-2000   Cancer Committee Member  
               Los Angeles County + University of Southern California Medical Center  
 1997-2000   Associate Director of Molecular Pathology Laboratory  
               Los Angeles County + University of Southern California Medical Center  
 1998-2005   Gynecology Oncology Research Committee Member,  
               University of Southern California and Yale University School of Medicine  
 2002-2004   Grand Round Coordinator and Organizer  
               Department of Pathology, Yale University School of Medicine  
 2000-        Invited Grant Reviewer for gynecologic cancer, China Natural Science Foundation,  
               Beijing, China  
 2001-2005   Selection Committee for Gynecologic Oncology Fellow  
               Department of Obstetrics and Gynecology, Yale University School of Medicine  
 2001-2005   Director of Gynecologic Pathology Fellowship Program  
               Department of Pathology, Yale University School of Medicine,  
 2002-2005   Director of Gynecologic Pathology Program, 01/02—07/05  
               Department of Pathology, Yale University School of Medicine  
 2003-2005   Committee member of The Ovarian Cancer Prevention and Early Detection Program at  
               Yale University  
 2003—2005   Faculty Search Committee, Department of Pathology  
               Yale University School of Medicine  
 2005-        Senior Consultant for Gynecologic Pathology and Gynecologic Oncology  
               Arizona Cancer Center and the University of Arizona  
 2005-        Director of Molecular Pathology  
               Department of Pathology, University of Arizona  
 2005- 2008   **Outstanding Principal Investigator**, Pathology Center, Fudan University School of  
               Medicine, China  
 2005-2008   **Distinguished professor and senior scientific advisor in pathology**, Fudan University  
               School of Medicine, China  
 2005- 2008   **Chairman of the Department of Pathology and Pathology Center**, Shanghai Medical  
               College Fudan University, China

Curriculum Vitae---Wenxin Zheng, M.D.

2005-2008 **Senior consultant** for the Department of Pathology, Pathology Center, and the Hospital of Obstetrics and Gynecology, Shanghai Medical College Fudan University, China

2006--2010 Member of Better than Ever Grant Review Committee  
Arizona Cancer Center, University of Arizona

2006- Committee member of Arizona Cancer Center, Cancer Genetics and Molecular Biology program, University of Arizona

2006- Member of Pathology Committee, **Gynecologic Oncology Group, USA**

2006- Member of Cancer Prevention Committee, **Gynecologic Oncology Group, USA**

2007- Member of Executive Administrative Committee, Department of Pathology, University of Arizona

2007- Member of Academic Review Committee, Department of Pathology, University of Arizona

2007- Member of Faculty Search Committee, Department of Pathology, University of Arizona

2008 - Member of Curriculum Committee, University of Arizona College of Medicine

2008 - South West Oncology Group, Gynecologic Oncology Committee, Pathology section, USA

2008- Co-Director of Tissue Acquisition and Cellular/Molecular Analysis Shared Service, Arizona Cancer Center, University of Arizona.

2008- Honorary Professor, Shangdong University School of Medicine, China

2013- Honorary Professor, Chinese Traditional Medical University, Nanjing, China

## OTHER EXPERIENCES

May 1998 Visiting Professor, Shanghai Second Medical University

Nov. 2003 Visiting Professor, Fudan University School of Medicine

Nov. 2003 Visiting Professor, Jiaotong University Medical School

March 2004 Visiting Professor, Hebei Medical University, Shijiazhuang, China

April 2004 Visiting Professor, Department of Pathology and Arizona Comprehensive Cancer Center, University of Arizona

July 2004- Distinguished Professor of Pathology and Gynecology and Senior Consultant for Gynecologic Pathology, Hospital of Obstetrics and Gynecology, Shanghai Medical College Fudan University

1997-2001 The Founder President of Association of Chinese American Physician, California.

2001- Member of Board of Directors, Association of Chinese American Physicians.

2004- 2006 Executive Committee member and Treasurer, International Association of Chinese Pathologists, USA.

2004-2005 Executive vice president of Association of Chinese American Physician (in charge of New England Area).

March 2005 Visiting professor and keynote speaker on the topic of endometrial cancer in Jinan, Shangdong University School of Medicine, China

May 2006 Visiting professor and keynote speaker on the topic of endometrial carcinogenesis in Chengdu, Sichuan University School of Medicine, China

May 2007 Visiting professor and keynote speaker on the topic of ovarian epithelial carcinogenesis in Department of Pathology, Beijing University School of Medicine, China

May 2008 Visiting professor and keynote speaker on the topic of endometrial cancer in Jinan, Shangdong University School of Medicine, China

Curriculum Vitae---Wenxin Zheng, M.D.

Jan. 2008- Executive Committee member, Chinese American Pathologist Association, USA.  
 2008- Abstract Review Committee, USCAP  
 2010- House of Delegate member, Arizona, CAP  
 2011- Chair of Arizona House of Delegate, CAP  
 2013- Nomination Committee, CAP

Who's Who in America - 62nd Edition, 2007

Who's Who in America - 63rd Edition, 2008

Who's Who in America - 64th Edition, 2009

Who's Who in America - 65th Edition, 2010

Who's Who in America - 66th Edition, 2011

Who's Who in America - 67th Edition, 2012

Who's Who in the World - 26th Edition, 2008

Who's Who in Science and Engineering - 11th Edition, 2010

Who's Who in Science and Engineering - 12th Edition, 2011

Who's Who in Science and Engineering - 13th Edition, 2012

## **SPECIFIC TEACHING RESPONSIBILITIES**

1996- Gynecologic Pathology teaching for residents and fellows in Departments of Pathology, Obstetrics and Gynecology, University of Southern California, Yale University and the University of Arizona  
 1996—2000 Cytology (gynecologic and non-gynecologic cytology) teaching for pathology residents and fellows, University of Southern California  
 1996-2005 Cytologic and biopsy correlation conference, University of Southern California and Yale University  
 1998-2005 Medical students, second year pathology course tutorial teaching, University of Southern California and Yale University  
 2006- Medical Students, second year pathology course 801, 6 lectures on gynecologic pathology, University of Arizona  
 2007- Medical Students, second year pathology course, life cycle block, 20 hours/year University of Arizona

## **MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

Local:

1995-1996 Rhode Island Society for Pathologist  
 1996-2002 Los Angeles Society for Pathologists  
 2002-2005 Connecticut Society for Pathologists  
 2010- Arizona Society for Pathologists

National and International:

1995- International Academy of Pathology (IAP)  
 1995- United States and Canadian Academy of Pathology (USCAP)

Curriculum Vitae---Wenxin Zheng, M.D.

1997-	International Society of Gynecologic Pathology (ISGP)
1995-2002	American Society of Investigative Pathology (ASIP)
1992-	College of American Pathologist (CAP)
1990-1995	The Endocrine Society
1990-2005	Chinese American Medical Society
1995-	Association of Chinese American Physicians
2001-2008	International Association of Chinese Pathologists
2004-	Chinese American Pathologist Association
2004-	American Board of Hospital Physicians
2006-	Arthur Purdy Stout Society (APSS)
2006-	Chinese Pathology Directors' Association
2007-	American Association of Cancer Research (AACR)
2014-	American Society of Colposcopy and Cervical Pathology (ASCCP)

## RESEARCH ACTIVITIES

Major Areas of Research Interest:

Gynecologic Oncology, particularly focus on ovarian, endometrial and cervical cancers.

Research Interests and my Original Creative Thoughts:

**Type II endometrial carcinogenesis.** I am the pioneer investigator for this project. In the last 12 years, together with colleagues, collaborators, and trainees, I have defined the precancer lesion and latent precancers (p53 signature). Based on our recent findings, I have proposed a new model of endometrial serous carcinoma (ESC) development, that is it starts from p53 signature glands to endometrial glandular dysplasia (EmGD) through serous endometrial intraepithelial carcinoma (EIC), then to the full-blown ESC. We are currently focusing on developing a mutant p53 protein based immunoassay for early detection of type II endometrial cancer. Active research is in process.

**Ovarian serous carcinogenesis.** It is known that majority ovarian high-grade serous carcinoma is derived from fallopian tube. Recently, we have obtained strong evidence that low-grade ovarian serous carcinoma is also mainly derived from fallopian tube. Now the main question become if ovary has any true epithelial cancer. These updates will have a tremendous impact in ovarian cancer prevention and management in near future.

**Cervical cancer early diagnosis and treatment.** I have been interested in cervical cancer early diagnosis and one-stop treatment for several years. Current drawback of cervical cancer management modality is the cumbersome lengthy diagnostic procedures and ineffective treatment methods. Together with collaborators in China, I have developed an efficient diagnostic and therapeutic approach for cervical precancers called as "One Stop Cervical Care". With this novel approach, we are able to offer definitive diagnosis and treatment for cervical HSIL in a less than 2-hour period.

**Origin of endometriosis.** It is controversial for a long time regarding what is the source for endometriosis. We recently defined the earliest morphologic changes of ovarian endometriosis called as **initial endometriosis**. This work leads us to further studies the



Curriculum Vitae---Wenxin Zheng, M.D.

etiology of endometriosis and the relationship between endometriosis and endosalpingiosis, and endocervicosis. Based on our understandings, these three conditions are inter-changeable via a metaplastic process. We are currently seeking for the biologic mechanisms of the metaplasia in these conditions. For instance, what is the cause or causes to make endosalpingiosis become endometriosis. At the present, the initial endometriosis provides a useful morphologic model to study the process. More interestingly, we recently obtained a morphologic and cellular evidence that at least some of the pelvic endometriosis is also derived from tubal mucosal cells.

Grants Awarded in Past 15 Years:

**Co-investigator (100%)** with Dr. Anthony R. Bellve (PI).  
Seminiferous growth factor of mammalian spermatogenesis \$280,896  
National Institute of Health, HD 29010.  
1992-1995

**Principle Investigator (5%)**  
Ovarian tumorigenesis and gonadotropins \$14,500  
James H. Zumberge Faculty Research and Innovation Fund  
1997-1998

**Principle Investigator (5%)**  
Ovarian carcinoma and gonadotropin receptors \$15,000  
American Cancer Society Institutional Research Grant  
Norris Comprehensive Cancer Center, University of Southern California  
Aided by grant #IRG-21-37 from the American Cancer Society  
1997-1998

**Principle Investigator (10%)**  
FSH as a key growth promoter in ovarian epithelial tumorigenesis \$50,000  
Robert E. and May Wright Foundation  
1998-1999

**Principle Investigator (10%)**  
Clinical Trial of Ovarian Cancer Prevention with Lupron \$10,000  
Rockefeller Foundation China Bridge Institution (North America)  
1998-2001

**Principle Investigator (30%)**  
FSH as a key growth promoter  
in the development of ovarian epithelial tumor  
\$366,119  
California Cancer Research Program, #2N10178  
2002-2004

**Co-Principal Investigator (10%)** with Dr. Brian Bagley (PI)  
A tissue based proteomic study for ovarian cancer markers \$750,000/yr  
National Institute of Health, 1R41CA128145

Curriculum Vitae---Wenxin Zheng, M.D.

2008 – 2010

**Co-PI (10%)** with Dr. Setsuko Chambers (PI).

Regulation of CSF-1 in ovarian cancer

\$1,635,000

National Institute of Health, RO1CA097347-01

2004-2009

**Principal Investigator** (10%)

Precursors of type II endometrial cancer

\$60,000

Arizona Cancer Center Better than Ever Grant

2006 – 2008

**Co-Principal Investigator** (1%) with Dr. Anna Maria Lopez (PI)

Ultraclinic through telepathology and telecolposcopy

to treat cervical cancer precursor lesions

\$25,000

Arizona Cancer Center Better than Ever Grant

2006 – 2008

**Active Grants****Co-Principal Investigator** with Dr. Guang Yao (5%)

Molecular mechanisms of tubal secretory cells in ovarian serous carcinogenesis \$40,000

Arizona Cancer Center Better than Ever Grant

2013 – 2014

**Co-Principal Investigator** with Dr. Guang Yao (5%)

Molecular mechanisms of tubal secretory cells in ovarian serous carcinogenesis \$25,000

Arizona Cancer Center Supporting Grant

2013 – 2014

5P30 CA023074-31 (Alberts)

7/1/09 – 6/30/14

0.12 calendar

NIH/NCI

\$114,713 (Co-Dir., Tissue Acquisition Shared Svc)

Cancer Center Support Grant

The major goal of this project is to provide organizational infrastructure for the promotion of interdisciplinary research and the collective use of resources.

R01 CA115780 (Gmitro)

7/1/10 – 6/30/14

0.5 calendar

NIH/NCI

\$192,884 (collaborator)

Diagnosis of Ovarian Cancer by Confocal Microendoscopy

The objective of this research is to develop and demonstrate a screening tool for early detection of ovarian cancer based on in situ visualization of tissue at the cellular level.

2R01 CA115780-05A1 (Gmitro)

9/1/05 – 4/30/14

0.60 calendar

NIH/NCI

\$1,854 (Salary only)

Diagnosis of Ovarian Cancer by Confocal Microendoscopy

Curriculum Vitae---Wenxin Zheng, M.D.

The major goal of this project is to develop and demonstrate a screening tool for early detection of ovarian cancer based on in situ visualization of tissue at the cellular level.

3R01 CA115780-05A1S1 (Gmitro) 9/1/05 – 4/30/14 0.60 calendar  
NIH/NCI \$29,369 (Salary only)

Diagnosis of Ovarian Cancer by Confocal Microendoscopy

The major goal of this project is to develop and demonstrate a screening tool for early detection of ovarian cancer based on in situ visualization of tissue at the cellular level.

## OTHER PROFESSIONAL ACTIVITIES

International, national, and regional Committee Assignment and Consultantship:

1999-2005	Referee, The Wellcome Trust, London, England
2000-2004	Referee, Hong Kong Research Grants Council
2004-	Research study section, Ovarian Cancer Research Fund, Natural Science Foundation of China
2006-	Promotion and Tenure committee, Department of Pathology, College of Medicine, University of Arizona.
2007-2010	Curriculum committee, College of Medicine, University of Arizona
2008-2013	Abstract Review Board, USCAP
2010-	House of Delegate, CAP
2011-	Chair, House of Delegate, CAP
2012-	Grant reviewer, Katar Scientific Foundation, Katar.
2013-	Nomination Committee, CAP

### Editorship:

**Co-Editor-in-Chief:** <http://www.ajceog.us>

American Journal of Clinical and Experimental Obstetrics and Gynecology

### Editorial Board:

American Journal of Cancer Research  
American Journal of Translational Research  
Journal of Hematology and Oncology (2007 to 2009)  
International Journal of Clinical and Experimental Pathology  
Chinese Journal of Clinical and Experimental Pathology  
The Scientific World JOURNAL  
Journal of Clinical and Experimental Pathology  
Journal of Cancer Research  
The Journal of Surgical Oncology  
The Journal of Anatomic Pathology

Ad Hoc Reviewer for the following peer reviewed Journals (1-5/year):

American Journal of Pathology  
American Journal of Surgical Pathology  
American Journal of Obstetrics and Gynecology

Curriculum Vitae---Wenxin Zheng, M.D.

Applied Immunohistochemistry and Molecular Morphology  
 Cancer Prevention  
 Clinical Cancer Research  
 Fertility and Sterility  
 Gynecologic Oncology  
 Obstetrics and Gynecology  
 International Journal of Cancer  
 International Journal of Gynecologic Pathology  
 International Journal of Gynecologic Cancer  
 Laboratory Investigation  
 Journal of National Cancer Institute  
 Neoplasia  
 International Journal of Women's Health  
 Human Pathology  
 Modern Pathology  
 PLoS One  
 Proc Natl Acad Sci  
 Cancer Prevention

#### Research Trainees:

1998-2000	Jean J. Lu, M.D., Postdoctoral Fellow, supported by American Cancer Society grant
2001-2002	Billur Z. Senturk, M.D., Postdoctoral Fellow, supported by Department of Pathology, Yale University
2003-2004	Emine Cagnur Ulukus. M.D., Postdoctoral research fellow, supported by Turkish Government
2004-2005	Ying Qin, M.D., M.Sc., Postdoctoral research fellow, supported by Chinese government.
2006-2008	Xiaofang Yi, MD, PhD, Postdoctoral research fellow, supported by Chinese government.
2009-2011	Nisreen Abushahin, MD, Gynecologic pathology fellow, supported by Jordan government.

#### Graduate Students:

2006-2008	Yongjuan Liu, Master of Science, Department of Pathology, Fudan University
2006-2009	Zhenbo Zhang, PhD, Department of Obstetrics and Gynecology, Fudan University
2006-2008	Lin Jia, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2007-2009	Xi Zhang, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2008-2010	Ning Chen, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2009-2011	Li Xiang, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2011-2012	Jie Li, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2013-2014	Zeng Yuan, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.
2013-2014	Wenjing Zhang, MD, a PhD candidate of Shandong University, co-sponsored by both the University of Arizona and the Shandong University in China.

## Curriculum Vitae---Wenxin Zheng, M.D.

## Clinical Fellow Trainees:

1998-1999	Charles Amenzca, M.D., Gynecologic Pathology Fellow, Department of Pathology, University of Southern California
2001-2002	Reena Jain, M.D., Gynecologic Pathology Fellow, Department of Pathology, Yale University.
2002-2003	Sharon Liang, M.D., Gynecologic Pathology Fellow, Department of Pathology, Yale University.
2003-2004	Roy Zhang, M.D., Gynecologic Pathology Fellow, Department of Pathology, Yale University.
2004-2005	Olu Fadare, M.D., Gynecologic Pathology Fellow, Department of Pathology, Yale University.
2003-2006	Jessica Mcalpine, M.D., Gynecologic Oncology Fellow, Department of Obstetrics and Gyneoclogy, Yale University.
2009	Wenxia Wang, MD, Gynecologic Oncology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona.
2010	Lijie Wang, MD, Gynecologic Oncology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona.
2010	Binlie Yang, MD, Gynecologic Oncology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona.
2010-2012	Nisreen Abushahin, MD, Gynecologic pathology fellow, Department of Pathology, University of Arizona
2011	Shujie Pang, MD, Gynecologic pathology fellow, Department of Pathology, University of Arizona
2011	Rutie Yin, MD, Gynecologic Oncology and Pathology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona.
2012	Yan Ning, MD, PhD, Gynecologic Pathology Fellow, Department of Pathology, University of Arizona
2012	Yiying Wang, MD, PhD, Gynecologic Oncology and Pathology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona
2012	Yue Wang, MD, Gynecologic Oncology and Pathology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona
2013	Dake Li, MD, Gynecologic Oncology and Pathology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona
2013	Lingmin Li, MD, PhD, Gynecologic Pathology Fellow, Department of Pathology, University of Arizona
2013	Yuan Lu, MD, PhD, Gynecologic Oncology and Pathology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona
2014	Binlie Yang, MD, Gynecologic Oncology Fellow, Department of Obstetrics and Gyneoclogy and Department of Pathology, University of Arizona.

Invited Presentations in the national and international universities and institutions for the occasions of Grand Rounds, Seminars, Meetings, and Courses

1. Columbia University, Department of Obstetrics and Gynecology, May 1990  
Title: The role of seminiferous growth factor (SGF) in spermatogenesis.

## Curriculum Vitae---Wenxin Zheng, M.D.

2. Cornell University, Department of Pathology, September 1992  
Title: The role of gonadotropins in the pathogenesis of ovarian epithelial cancer
3. Memorial Sloan-Kettering Cancer Center Grand Round, October 1993  
Title: Borderline tumor of the fallopian tube, does it exist?
4. Cornell University, Department of Pathology, February 1994  
Title: Endometrial cancer, a possible dualistic model to explain its pathogenesis
5. Brown University, Department of Pathology, January 1995  
Title: FSHR in ovarian surface epithelium and epithelial tumors
6. Harvard University, Department of Obstetrics and Gynecology Endocrine Unit, October 1995, Title: The role of menstrual hormones in the development of ovarian epithelial cancer.
7. University of Southern California, Department of Pathology, May 1996  
Title: Gonadotropin responsive cells and BRCA1 expression in ovarian cells: clues for the hormonal etiology of ovarian cancer development.
8. University of Southern California, Department of Pathology Grand Round, April 1997  
Title: Endometrial carcinogenesis: hormone and non-hormone related issues
9. University of Southern California, Department of Pathology, May 1998  
Title: The role of inhibin alpha in the diagnosis of ovarian sex cord-stromal tumor
10. University of Southern California, Norris Cancer Center, November 1998  
Title: The role of gonadotropins in the development of ovarian epithelial tumors
11. University of California Davis, Department of Pathology, May 1999  
Title: FSH plays a key role in the development of ovarian epithelial tumors.
12. University of California Los Angeles, Department of Pathology, January 2000  
Title: The role of gonadotropins in the development of ovarian epithelial tumors.
13. University of California Los Angeles, Olive View Medical Center, Department of Pathology, March 2000  
Title: Diagnosis of ovarian cancers: morphologic criteria and new bio-markers
14. Bayer Company, Oakland, California, May 2000  
Title: Tissue microarray and molecular pathology
15. University of California Irvine, Department of Pathology, California, September 2000  
Title: The role of menstrual hormones in the etiology of ovarian epithelial tumorigenesis.
16. Emory University, Department of Pathology Grand Round, GA, September 2000  
Title: The role of menstrual hormones in the etiology of ovarian epithelial tumorigenesis.
17. University of Massachusetts, Department of Pathology, MA, October 2000  
Title: The role of menstrual hormones in the etiology of ovarian epithelial tumorigenesis.
18. Yale University School of Medicine, Grand Round of Department of Radiation Therapeutics, May 2001  
Title: Endometrial carcinogenesis, current understanding and clinical application.
19. Yale Cancer Center, Ovarian Cancer Program, November 2001  
Title: The role of menstrual hormones in the development of ovarian epithelial tumors.
20. Jiaotong University Medical School, Shanghai, November 2003  
Title: Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma.
21. Fudan University Shanghai Medical College, Hospital of Obstetrics and Gynecology, November 2003  
Title: Endometrial carcinogenesis, an update
22. University of Massachusetts, Department of Pathology, March 2004



Curriculum Vitae---Wenxin Zheng, M.D.

- Title: Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: diagnostic criteria and clinical impact.
23. Heibei University School of Medicine, Department s of Obstetrics and Gynecology and Pathology, March 2004
- Title: UPSC carcinogenesis with emphasis on newly identified precursor lesions.
24. University of Arizona, Department of Pathology, April 2004
- Title: Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma.
25. Harvard University, Brihgam and Women's Hospital, Department of Pathology, May 2004
- Title: Precursor lesions of type II endometrial cancer.
26. New York University School of Medicine, Department of Pathology, October 2004
- Title: Precursor lesions of uterine papillary serous carcinoma.
27. Yale University, Ella Grasso Annual Conference, November 2004
- Title: Is UPSC precursor lesions recognizable?
28. Department of Pathology, Beijing University School of Medicine, December 2004
- Title: Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: diagnostic criteria and clinical impact.
29. Ruikang Pharmaceutical Company, Beijing, China, December 2004
- Title: Spermatogenesis and herbal medicines promoting its process.
30. State University of New York, Stony Brook Medical Center, Department of Pathology, February 2005
- Title: Endometrial cancer precursor lesions: diagnosis and practical guidelines for the clinical management
31. **Keynote Speaker** in International Gynecologic and Urogenital Pathology Annual meeting, Jinan, Shandong Province, China, March 31 to April 1, 2005
- Title: Endometrial cancer, practical issues, recent progress and future directions.
32. Shanghai Cancer Hospital, Fudan University School of Medicine, China, April 6, 2005
- Title: Uterine papillary serous carcinoma, its early form and precursor lesions: diagnosis and practical guidelines and clinical management.
33. Department of Pathology, Hospital of Obstetrics and Gynecology, Fudan University School of Medicine, April 8, 2005.
- Title: Practical review of gynecologic pathology cases
34. Department of Pathology and Obstetrics and Gynecology, Qilu Hospital, Shangdong University School of Medicine, October 8-9, 2005.
- Title: Dualistic model of ovarian carcinogenesis
35. **Keynote Speaker** in The 8<sup>th</sup> Chinese National Gynecologic Pathology Conference, Hangzhou, China, October 25 to 28, 2005
- Title: A. Recent progresses on non-endometrioid endometrial carcinogenesis. B. Ovarian borderline tumors – diagnostic criteria and practical issues.
36. Shanghai Cancer Hospital, Shanghai Medical College, Fudan University China, Oct. 25 2005
- Title: Ovarian carcinogenesis, a proposed dualistic model.
37. Arizona Cancer Center, Tucson, Arizona. In the 37<sup>th</sup> Annual Tucson Seminar focus on women's cancers. January 26 – 28, 2006.
- Title: Rapid analysis, Breast biopsies, Telepathology.
38. The Chinese Association of Obstetrics and Gynecology, Shanghai. June 27, 2006

Curriculum Vitae---Wenxin Zheng, M.D.

- Title: Ovarian Borderline Tumors, the consensus, controversies, practical recommendations, and future directions.
39. Guangxi Medical University, China. June 23 to 24, 2006  
Title: Endometrial carcinogenesis and diagnostic problems in daily practice.
40. School of Medicine, Shandong University, China. June 30, 2006  
Title: Ovarian Borderline Tumors, the consensus, controversies, practical recommendations, and future directions.
41. Qingdao Municipal Hospital, Shandong, China. July 1 to 2, 2006  
Title: **Honorary lecture as a distinguished guest professor:** Cervical cancer precursor lesions and their morphologic mimics.
42. Shanghai Medical College Fudan University, China. September 4, 2006  
Title: Pathology Introduction to class 2008 medical students.
43. The Sixth meeting of the Association of Directors of Pathology of China. Qingdao, Shandong, China. September 9 to 10, 2006  
Titles: (1) **Pathology reform and future directions in China, an experience from Fudan University.** (2) Precursor lesions of type II endometrial cancers.
44. The 4<sup>th</sup> Chinese national tumor pathology diagnostic conference. Huangshan, Anhui, China. September 16 to 17, 2006  
Titles: (1) Precursor lesions of type II endometrial cancers. (2) Practical issues of ovarian mass diagnosis and differential diagnosis.
45. The first Shanghai gynecologic pathology conference. Shanghai, China. September 23, 2006. **Conference organizer, chair, moderator, and speaker.**  
Lecture Title: Endometrial serous carcinoma, pathogenesis, precursor diagnosis, and future directions.
46. Fudan Pathology Center – MD Anderson Cancer Center Joined Pathology symposium, Shanghai China, March 8 – 11, 2007. **Symposium organizer, chair, moderator, and speaker**  
Lecture Title: Recent progresses of type II endometrial cancers
47. Shanghai Medical Association – Obstetrics and Gynecologic Group conference, March 19, 2007.  
Title: A dualistic model of ovarian carcinogenesis
48. 5<sup>th</sup> Asia Pacific International Academy Pathology Congress, Singapore, May 27 to 29, 2007. **Invited speaker:**  
Title: Type II endometrial cancer: precancers and carcinogenesis
49. Annual conference of Arizona Pathology Association, Pheonix, AZ, May 3<sup>rd</sup>, 2008. **Invited Speaker**  
Title: Precancers of type II endometrial cancer
50. Beijing Pathology Association, China, June 15 to 16, 2008. **Invited Speaker**  
Title: Source of pelvic serous carcinomas
51. China Automation Institute, Beijing, China, June 14, 2008 **Invited Panel Speaker**  
Title: The role of social computing in medical sciences
52. Four major cities in China: Beijing, Shanghai, Chengdu, and Guangzhou, Feb. 11 to 19, 2009  
Cervical Cancer Workshop  
**Co-organizer and Chair with Dr. Kenneth Hatch and speaker**



Curriculum Vitae---Wenxin Zheng, M.D.

53. Title: Trends of cervical cancer prevention  
Beijing University, China, Feb. 13 and 18, 2009  
**Invited speaker**  
Tumor board conference, formality and reality in the world.
54. Sichuan University, China, Feb. 13 and 18, 2009  
**Invited speaker**  
Recent advances in Gynecologic Pathology
55. Lowers Vantana Canyon Resort, Tucson, Arizona, Feb. 2 to 6, 2010  
ASCP teaching course: Gynecologic Pathology: A practical surgical and cytology perspective  
**Faculty**  
Type II endometrial precancer, pathologic diagnosis and clinical management.
56. University of Ottawa, Ontario, Canada, April 14 and 15, 2010  
**Invited speaker**  
Endometrial precancers and carcinogenesis  
Portfolios of Gynecologic Pathology (4 hours)
57. Gynecologic Pathology Teaching Course  
Shandong University, China, May 14 to 16, 2011  
**Keynote speaker**  
Recent advances in endometrial, ovarian, and cervical carcinogenesis (6 hours total)
58. Beijing University, China, May 25, 2011  
**Invited speaker**  
Endometrial serous carcinoma: pathologic diagnosis and clinical impact
59. Shanghai Health Department, May 27 to 29, 2011  
**Invited speaker**  
Lectures: Ovarian epithelial carcinogenesis and clinical impact  
Advances of endometrial cancer and clinical management  
Cervical cancer screening and early detection: what are the key points?
60. Arizona Cancer Center, October 19, 2011  
**Grand round speaker**  
Lecture: Does ovarian epithelial cancer arise in the ovary?
61. Annual conference of Arizona Pathology Association, Tucson, AZ, April 3, 2012.  
**Faculty speaker**  
Title: Recent advances in ovarian and endometrial cancer pathology.
62. Shandong University, China, May 20, 2012  
**Invited visiting professor speaker**  
Title: Ovarian cancer does not come from ovary. What is the cell origin?
63. Nanjing Univeristy and Nanjing Annual Pathology Meeting, China, May 27, 2012  
**Invited speaker**  
Title: Endometrial serous carcinoma without papillary structure, how to recognize correctly?
64. Shanghai Municipal Health Bureau, China, May 30, 2012  
**Invited speaker**  
Title: Cervical cancer prevention and screening
65. IAP October 2012, South Africa, Endometrial pathology course  
**Faculty**  
Lecture: Endometrial serous carcinoma and its precursors, carcinogenesis and diagnosis

Curriculum Vitae---Wenxin Zheng, M.D.

66. University of California, Irvine, January 24, 2013  
**Grand round speaker**  
 Lecture: Endometrial serous carcinoma and its precursors: diagnostic pitfall and clinical implications.
67. Annual conference of Arizona Pathology Association, Tucson, AZ, April 14, 2013.  
**Faculty speaker**  
 Title: How to recognize gynecologic cancer cells from pelvic washing specimens?
68. The 12<sup>th</sup> Chinese National Gynecologic Pathology Conference, Jinan, China, May 24-25, 2013  
**Invited speaker**  
 Title: Diagnostic criteria for endometrial hyperplasia and differential diagnosis from well differentiated endometrioid carcinoma.
69. The 12<sup>th</sup> Chinese National Gynecologic Pathology Conference, Jinan, China, May 24-25, 2013  
**Invited speaker**  
 Title: How to recognize progestin induced pathologic changes and make correct pathology report guiding clinical management
70. Cervical precancer teaching course, Huantai, Shandong, China, May 17, 2013  
**Invited speaker**  
 Title: Cervical cancer prevention: current situation and future strategies
71. Bingzhou Medical College, Yantai, China, May 10, 2013  
**Invited speaker**  
 Title: Recent advances in gynecologic cancers
72. Shanghai Pudong Health Bureau, China, May 30, 2013  
**Invited speaker**  
 Title: Updating cervical cancer screening guidelines
73. Shanghai Pudong Health Bureau, China, October 24, 2013  
**Invited speaker**  
 Title: Ovarian borderline malignancies: what are the key points?
74. Chinese Gynecologic Oncology 10<sup>th</sup> National Annual Conference, Nanjing, China, October 26, 2013  
**Invited Expert Lecture**  
 Title: Ovarian serous borderline tumors: Consensus, clinical impacts, and future directions.
75. Chinese Pathology Association National Annual Conference, Guangzhou, China, November 8, 2013  
**Invited Expert Lecture**  
 Title: Endometrial serous carcinoma and its precancer: diagnosis and clinical implications.
76. Shanghai Pudong Health Bureau, China, May 14, 2014  
**Invited speaker**  
 Title: Recent advances of cervical cancer in the last 2 years.
77. Shanghai International Women and Infants' Hospital, China, May 15, 2014  
**Invited speaker**  
 Title: Cervical cancer screening and the ideas of application in China 宫颈癌筛查最新进展及其在中国应用的思考

Curriculum Vitae---Wenxin Zheng, M.D.

78. Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, China, May 16, 2014  
**Invited speaker**  
Title: Fallopian tube: under the spotlight
79. China-USA molecular pathology and its application cause, Nanjing, China, June 3, 2014  
**Invited speaker**  
Title: Fallopian tube: under the spotlight
80. Qilu Hospital, Shandong University, China, May 15, 2014  
**Invited speaker**  
Title: Recent advances of cervical cancer prevention in the last 2 years. 宫颈癌筛查最新进展及其在中国应用的思考

## BIBLIOGRAPHY

### Peer Reviewed (\*Corresponding author articles):

- 1). Bellve AR, **Zheng W**. Seminiferous growth factors as autocrine and paracrine modulators of male gonadal functions. J Reprod Fertil. 1989; 85, 771-793
- 2). Bellve AR, **Zheng W**. Different pleiotypic actions of SGF,  $\alpha$ FGF and  $\beta$ FGF. Ann N Y Acad Sci 1989; 564, 116-131.
- 3). **Zheng W**, Butwell T, Hecket L, Griswold M, Bellve AR. Pleiotypic actions of the seminiferous growth factor on two testis cell lines: comparisons with acidic and basic fibroblast growth factors. Growth Factor 1990; 3, 73-82
- 4). Braunhut SJ, Rufo GA, **Zheng W**, Enisse BJ, Bellve AR. Seminiferous growth factor (SGF) induces the proliferation of transformed Sertoli cells. Biol Reprod 1990; 42, 639-648
- 5). Bellve AR, **Zheng W**, Martinova YS. Recovery, capacitation, acrosome reaction, and fractionation of sperm. Methods Enzymol. 1993, 225:113-36.
- 6). Zheng W, Yang GC, Godwin TA, Caputo TA, Zuna RE. Mucinous adenocarcinoma of the endometrium with intestinal differentiation. Human Pathol 1995, 26: 1385-8.
- 6). **Zheng W**, Wolf S, Kramer EE, Hoda S. Borderline serous tumor of the fallopian tube. Am J Surg Pathol 1996; 20, 30-35
- 7). **Zheng W**, Magid MS, Kramer EE, Chen YT. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 1996; 148, 47-53
- 8). \***Zheng W**, Cao P, Zheng M, Kramer EE, Godwin T. p53 and bcl-2 expression in endometrial adenocarcinoma. Comparison of serous and endometrioid subtypes (see comments). Gynecol Oncol 1996; 61, 167-174

Curriculum Vitae---Wenxin Zheng, M.D.

- 9). \***Zheng W**, Feng YJ, Gandhi M, Siu S, Hom E, Caputo T, Lauchlan SC. Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity. *Int J Gynecol Cancer* 1996; 6, 235-240
- 10). \***Zheng W**, Sung CJ, Cao P, Cai R, Godwin TA, Kramer EE, Lauchlan SC. The early occurrence and prognostic significance of p53 in primary carcinoma of the fallopian tube. *Gynecol Oncol* 1997; 64, 38-48
- 11). \***Zheng W**, Sung CJ, Hanna I, Lambert-Messerlian G, Steinhoff M, Lauchlan SC. Inhibin alpha and beta subunits of inhibin/activin as markers for gonadal sex cord-stromal differentiation. *Int J Gynecol Pathol*, 1997; 16, 263-271
- 12). Lambert-Messerlian G, Steinhoff M, **Zheng W**, Canick J, Seifer D, Schneyer A. Characterization of immunoreactive forms of inhibin in serum of pre- and post-menopausal women with epithelial ovarian cancer. *Gynecol Oncol* 1997; 65, 512-516
- 13). Welt CK, Lambert-Messerlian G, **Zheng W**, Sluss P, Crowley WF, Schneyer AL. Activin, inhibin and follistatin in epithelial ovarian carcinoma. *J Clin Endocrinol Metab* 1997; 82, 3720-3727
- 14).\***Zheng W**, Welt C, Lambert-Messerlian G, Sung CJ, Schneyer AL, Felix JC. Asymmetric Expression of Inhibin and Activin in Ovarian Epithelial Carcinoma. *Lab Invest* 1997, 76:112.
- 15) \***Zheng W**, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Schneyer A, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits of in primary epithelial ovarian cancer. *Gynecol Oncol* 1998; 69, 23-31
- 16) \***Zheng W**, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 as an significant diagnostic marker for uterine surface carcinoma--precursor lesion of uterine papillary serous carcinoma. *Am J Surg Pathol* 1998, 22: 1463-1473.
- 17) \***Zheng W**, Lauchlan SC. Inhibin and Activin: Their roles in ovarian tumorigenesis and their diagnostic utility in surgical pathology practice. *Appl Immunohistochem Mol Morphol* 1999, 7, 29-38.
- 18) Amezcua CA, \***Zheng W**, Muderspach L, Felix JC. Down regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. *Gynecol Oncol* 1999, 73, 126-136.
- 19) Quddus MR, Sung CJ, **Zheng W**, Lauchlan SC. p53 alteration in endometrial metaplasia with dysfunctional uterine bleeding. *Histopathology* 1999, 35: 44-49.
- 20) \***Zheng W**, Lu J, Luo F, Zheng Y, Feng Y-J, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by FSH and inhibition of the effect by LH. *Gynecol Oncol* 2000, 76: 80-88.
- 21).\***Zheng W**, Luo F, Lu J, Baltayan A, Press M, Zhang ZF, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer (see comment). *Gynecol Oncol*, 2000, 76: 294-300.

Curriculum Vitae---Wenxin Zheng, M.D.

- 22). Sung J, Quddus M, Zheng Y, Zhang ZF, Lauchlan SC, **\*Zheng W**. p53 serves as a significant prognostic marker in endometrial carcinomas. *Int J Gynecol Cancer*, 2000, 10: 119-127.
- 23). **\*Zheng W**, Lu JJ, Luo F, Zhang L, Cho M, Wang CY, Stanczyk F. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. *Am J Reprod Immunol*, 2000, 44, 104-113.
- 24). Lu JJ, Zheng Y, Kang X, Yuan J-M, Lauchlan SC, **\*Zheng W**. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. *Gynecol Oncol*, 2000, 79: 158-168.
- 25) Amezcua CA, Lu JJ, Stanczyk FZ, **\*Zheng W**. Apoptosis may be an early event of Progestin Therapy for endometrial hyperplasia. *Gynecol Oncol* 2000, 79, 169-176.
- 26) Wang J, Luo F, Chen P, Liu P, **\*Zheng W**. VEGF Expression and enhanced production by gonadotropins in ovarian epithelial tumors. *Intl J Cancer* 2002, 97: 163-167
- 27) Zhou H, Luo MP, Schönthal AH, Pike MC, Stallcup MR, Blumenthal M, **Zheng W**, Dubeau L. Effective of Reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. *Cancer Biol Therapy*, 2002, 1:300-306.
- 28) Chen C, Petittclerc E., Brook PC, Sun T, Yu MC, **Zheng W**, Dubeau L. Effective of Reproductive hormones on ovarian epithelial tumors: II. Effect on angiogenic activity. *Cancer Biol Therapy*, 2002, 1:307-314.
- 29). Wang J, Ling-Chang L, Schwartz PE, Lauchlan SC, **\*Zheng W**. Quantitative analysis of FSHR in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in peritoneal cavity. *Intl J Cancer*, 2003, 103: 328-334.
- 30). Wang S, Pudney J, Song J, Mor G, Schwartz PE, **\*Zheng W**. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia—precursor of endometrial cancer. *Gynecol Oncol*, 2003, 88: 108-117.
- 31). **\*Zheng W**, Senturk BZ, Parkash V. Inhibin Immunohistochemical Staining: A practical approach for the surgical pathologist in the diagnosis of ovarian sex cord-stromal tumors. *Adv Anat Pathol*, 2003, 10: 27-38.
- 32). Chu MC, Mor G, Lim C, **Zheng W**, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. *Gynecol Oncol*, 2003, 90: 170–176
- 33). Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, **Zheng W**, Luleci G. Arici A. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10 expression by estradiol and progesterone in human endometrium. *J Clin Endocrinol Metab*, 2003, 88: 5017-26.
- 34). Schwartz PE, and **\*Zheng W**. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. *Gynecol Oncol*, 2003, 90: 644-650.

Curriculum Vitae---Wenxin Zheng, M.D.

- 35). Cai KQ, Albarracin CT, Rosen DG, **Zheng W**, Zhong R, Broaddus R, Luthra R, Liu J. Microsatellite and Chromosomal Instabilities and Expression of hMLH1 and hMSH2 Proteins in Ovarian Clear Cell Carcinoma. *Human Pathol* 2004, 35: 552-559.
- 36) Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, **Zheng W**, Gershenson DM, Luthra R. Microsatellite Instabilities and Expression of hMLH1 and hMSH2 Proteins in Ovarian Endometrioid Cancer. *Modern Pathol* 2004. 17: 75-80
- 37) **Zheng W**, Baker HE, Mutter GL. Involution of PTEN-Null Endometrial Glands with Progestin Therapy. *Gynecol Oncol*, 2004, 92: 1008-1013.
- 38). \***Zheng W**, Liang SX, Yu H, Rutherford, T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: a morphological study. *Intl J Surg Pathol*, 2004, 12: 207-223.
- 39). Liang SX, Cheng L, Chambers SK, Zhou Y, Schwartz PE, \***Zheng W**. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: a molecular study. *Intl J Surg Pathol*, 2004, 12: 319-331
- 40). Yeh MM, Tang LH, Wang S, Robert ME, **Zheng W**, Jain D. Inhibin expression in ovarian-type stroma in mucinous cystic neoplasms. *Applied Immunohistochem Mol Morphol*, 2004, 12: 148-152.
- 41). Fadare O, \***Zheng W**. HER2 protein (p185<sup>HER2</sup>) is only rarely overexpressed in cervical cancer. *Intl J Gynecol Pathol*, 2004, 23: 410-411.
- 42). Cheng L, Thomas A, Roth LM, **Zheng W**, Michael H, Abdul-Karim FW. OCT4: a novel biomarker for dysgerminoma of the ovary. *Am J Surg Pathol* 2004. 28: 1341-1346.
- 43). Ma L, Fisk J, Crum CP, Zhang R, Ulukus EC, \***Zheng W**. Cervical eosinophilic dysplasia, a newly identified variant of high-grade squamous intraepithelial neoplasia of the cervix. *Am J Surg Pathol*, 2004, 28: 1474-1484.
- 44). Katsaros D, Cho W, Singal R, Fracchioli S, Rigault de la, Longrais IA, Puopolo M, Smith M, **Zheng W**, and Yu H. Methylation of tumor suppressor gene p16 and epithelial ovarian cancer survival, *Gynecol Oncol*, 2004, 94: 685-692.
- 45). Fadare O, **Zheng W**\*. Histologic dating of the endometrium: Accuracy, reproducibility, and practical value. *Adv Anat Pathol*, 2005, 12 39-46.
- 46). \***Zheng W**, Schwartz PE. Serous EIC as an early form of UPSC. Recent progress of its pathogenesis and current opinions of clinical management, *Gynecol Oncol*, 2005, 96: 579-582.
- 47). Ulukus M, Ulukus EC., **Zheng W**, Arici A. Expression of interleukin-8 receptors in endometriosis. *Human Reproduction*, 2005, 20: 794-801.



Curriculum Vitae---Wenxin Zheng, M.D.

- 48). \***Zheng W**, Li N, Wang J, Ulukus EC, Murat Ulukus M, Arici A, and Liang SX. Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis. *Intl J Gynecol Pathol*, 2005, 24: 164-172.
- 49). Ulukus EC, Ulukus M, **Zheng W**, Arici A. Expression of interleukin-8 and monocyte chemotactic protein-1 in adenomyosis. *Human Reproduction*, 2005, 20: 2958-2963.
- 50). \***Zheng W**. Eosinophilic Dysplasia of the cervix, which are the invasive and cytologic counterparts? *Am J Surg Pathol*, 2005, 29: 837-838.
- 51). Hileeto D, Fadare O, Martel M, \***Zheng W**. Endometrial Polyp in Postmenopausal Women Associated with an Increased Risk of Cancer Involvement, *World Oncology Surgical Journal*, 2005, 3: 8-10.
- 52). Toy EP, Bonafé M, Savlu A, Zeiss C, **Zheng W**, Chambers SK. Correlation of tumor phenotype with *c-fms* proto-oncogene expression in an *in vivo* intraperitoneal model for experimental human breast cancer metastasis. *Clinical and Experimental Metastasis*. 2005, 22: 1-9
- 53). Sever M, Jones TD, Roth LM, **Zheng W**, Michael H, Hattab EM, Emerson RE, Baldrige LA, Cheng L. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. *Mod Pathol*. 2005, 18: 1411-6.
- 54). Oluwole Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE and \***Zheng W**. E-cadherin and beta-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. *World Journal of Surgical Oncology*. 2005, 3: 38.
- 55). Fadare O, **Zheng W**. Well-Differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component. *Virchows Archiv*, 2005, 9: 1-5.
- 56). Chang KH, Albarracin C, Luthra R, Wang L, **Zheng W**, Malpica A, Deavers MT, Silva EG, Liu J. Discordant Genetic Changes in Ovarian and Endometrial Endometrioid Carcinomas: a Potential Pitfall in Molecular Diagnosis. *Intl J Gynecol Cancer*, 2006, 16, 178-182
- 57). Cossu-Rocca P, Jones TM, LM Roth LM, JN Eble JN, **Zheng W**, Karim FW, Cheng L. Cytokeratin and CD 30 Expression in Dysgerminomas. *Human Pathol*, 2006, 37: 1015-1021.
- 58). Fadare O, Liang SX, E. Cagnur Ulukus EC, Chambers SK, and \***Zheng W**. Precursors of Endometrial Clear Cell Carcinoma. *Am J Surg Pathol*, 2006, 30: 1519-1530.
- 59). Cossu-Rocca P, Roth LM, Eble JN, **Zheng W**, Michael H, Emerson RE, Jones TD, Cheng L: Chromosome 12p abnormalities in dysgerminoma of the ovary: A FISH analysis. *Modern Pathol*, 2006, 19: 611-615.
- 60) Ulukus M, Ulukus EC, Seval Y, Cinar O, **Zheng W**, Arici A. Expression of interleukin-8 receptors in patients with adenomyosis. *Fertil Steril*. 2006, 85:714-20.

Curriculum Vitae---Wenxin Zheng, M.D.

- 61) Risch HA, Bale AE, Beck PA and **Zheng W**. PGR +331A/G and Increased Risk of Epithelial Ovarian Cancer. *Cancer Epidemiol Biomarkers Prevention*, 2006 15: 1738-1741
- 62). Liang S, Stone G, Chalas E, Pearl M, Callan F, and **Zheng W**. A high-grade uterine leiomyosarcoma with human chorionic gonadotropin production. *Intl J Gynecol Pathol*, 2006, 25: 257-261.
- 63). Kong BH, **Zheng W**, Sheng XG, Zhang TG, Wang B, Wang LJ. Clinicopathologic issues of endometrial cancer: a panel discussion. *Prog Obstet Gynecol*, 2006, 15: 401-414.
- 64). Emerson RE, Wang M, Roth LM, **Zheng W**, Abdul-Karim FW, Liu F, Ulbright TM, Eble JN, Cheng L. Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors. *Int J Gynecol Pathol*. 2007, 26:368-374.
- 65) \***Zheng W**, Liang SX, Yi XF, Ulukus EC, Davis J, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. *Int J Gynecol Pathol*, 2007, 26: 38-52.
- 66). Howell NR, **Zheng W**, Cheng L, Kane P, Pearl M, Chalas, E, Liang SX. Carcinomas of ovary and lung with clear cell features: Can immunohistochemistry help in differential diagnosis? *Intl J Gynecol Pathol*, 2007, 26: 134-140.
- 67). Wang W, Guo T, Rudnick PA, Song T, Li J, Zhuang Z, **Zheng W**, Devoe DL, Lee CS, Balgley BM. Membrane proteome analysis of microdissected ovarian tumor tissues using capillary isoelectric focusing/reversed-phase liquid chromatography-tandem MS. *Anal Chem*. 2007, 79:1002-9.
- 68) Chandramouli A, Shi J, Feng Y, Holubec H, Shanas R, Bhattacharyya AK, **Zheng W**, Nelson MA. Haploinsufficiency of the *cdc2l* gene contributes to skin cancer development in mice. *Carcinogenesis*, 2007, 28: 2028-35. PMID: 17389615
- 70) Fadare O, Yi X, Liang SX, Ma Y, \***Zheng W**. Variations of Mitotic Index in Normal and Dysplastic Squamous Epithelium of the Uterine Cervix as a Function of Endometrial Maturation. *Modern Pathol*, 2007, 20: 1000-8.
- 71) Liang SX, Patel K, Pearl M, Liu J, **Zheng W**, Tornos C. Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha. *Int J Gynecol Pathol*. 2007, 26: 291-7.
- 72) \***Zheng W**, H Wang. Precursor lesions and its carcinogenesis of type II endometrial cancer. *J Clin Exp Pathol*, 2007, 23: 129-132 (as a format of Expert Forum).
- 73) \***Zheng W**, Wang H. The Borderline tumor: consensus and dilemma. *J Clin Exp Pathol*, 2007, 23: 257-261 (as a format of Expert Forum).
- 74) Wang H and \***Zheng W**. Precancers of type II endometrial cancer: diagnosis and clinical management. *China Pathol J*, 2007, 36: 505-507 (as an invited commentary).



Curriculum Vitae---Wenxin Zheng, M.D.

- 75) Yi X, \***Zheng W**. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. *Current Opinion Obstet Gynecol*, 2008, 20: 20-25.
- 76) \***Zheng W**, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The Oncofetal Protein IMP3: A Novel Biomarker for Endometrial Serous Carcinoma. *Am J Surg Pathol*, 2008, 32: 304-315.
- 77) Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjær SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, **Zheng W**, Pharoah PDP, Chenevix-Trench G, Pike MC, Schildkraut J & Berchuck A on behalf of the Ovarian Cancer Association Consortium (OCAC). Progesterone Receptor Variation and Risk of Invasive Epithelial Ovarian Cancer: Results from the Ovarian Cancer Association Consortium Pooled Analysis. *British J Cancer*, 2008, 98: 282-9.
- 78) Fadare O and **Zheng W**. Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. *Diagnostic Pathology* 2008, 3:6-10 (invited commentary).
- 79) Jia L, Liu YJ, Yi X, Liang SX, Miron A, Crum CP, Kong B\*, **Zheng W\***. Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting its Precancer Nature for Endometrial Serous Carcinoma. *Clinical Cancer Res*, 2008;14: 2263-9.
- 80) Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, **Zheng W**, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. *Fertil Steril*. 2009, 91:687-93. Epub 2008 Mar 7, PMID: 18314120
- 81) Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, **Zheng W**, Wondrak GT, Wong PK, Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis*. 2008, 29:1235-43 PMID: 18413364
- 82) Shahabi S, Nathan LM, Chanana C, Garrett WS, Zheng W, Rutherford TJ. Liver metastasis in a case of adenoid cystic carcinoma of the Bartholin's gland: a rare presentation. *Arch Gynecol Obstet*. 2008 Nov 9. [Epub ahead of print] PMID: 18998150
- 83) Fadare O, **Zheng W\***. Insights into endometrial serous carcinogenesis and progression. *Int J Clin Exp Pathol*. 2009, 2: 411-32. PMID: 19294001
- 84) H-H Woo, HH, Zhou Y, Yi X, David CL, **Zheng W**, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB and Chambers SK. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. *Oncogene*, advance online publication on 19 January 2009. PubMed PMID: 19151756
- 85) Zhang Z, Jia L, Feng Y, **Zheng W\***. Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. *Cancer Lett*. 2009, 278(1):56-64.

Curriculum Vitae---Wenxin Zheng, M.D.

- 86) Zhang Z, Jia L, Feng YJ, **\*Zheng W**. FSH receptor overexpression in ovarian epithelial tumors. *Clinics in Occupational and Environmental Medicine*, 2009, 278: 56-64.
- 87) Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, Jin H, Gu C, **Zheng W\***. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. *Modern Pathol*. 2009, 22: 699-708. PMID: 19287462
- 88) Yi X, Zhou Y, **Zheng W**, Chambers SK. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer. *Aust N Z J Obstet Gynaecol*. 2009; 49:93-8. PMID: 19281587
- 89) Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, **Zheng W\***. Molecular Identification of “Latent Precancers” for Endometrial Serous Carcinoma in Benign Appearing Endometrium. *Am J Pathol*, 2009, 74:2000-6. PMID:19435786
- 90) Sun Y, Zhang T, Gao P, Meng B, Gao Y, Wang X, Zhang J, Wang H, Wu X, **Zheng W**, Zhou G. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. *Breast Cancer Res Treat*. 2009 Aug 20. [Epub ahead of print] PMID: 19693666
- 91) Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang BL, Fadare O, Schwartz PE, Chambers SK, Kong B, **Zheng W\***. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years or younger. *Intl J Cancer*, 2011; 128: 763-770. PMID: 20473885
- 92) Jiang T, Chen N, Zhao F, Wang XJ, Kong B, **\*Zheng W**, Zhang DD\*. High Levels of Nrf2 determine Chemoresistance in Type II Endometrial Cancer. *Cancer Res*. 2010 Jun 8. PMID: 20530669
- 93) Kong BH, **\*Zheng W**. Opinions about diagnosis and treatment of cervical cancer and its precancerous lesions in China. *Chinese Medical Journal* 2010, 90: 3027-30.
- 94) Cheng L, Rott LM, Zhang S, Wang M, Morton MJ, **Zheng W**, Abdul Karim FW, Montironi R, Lopez-Beltran A. KIT Gene Mutation and Amplification in Dysgerminoma of the Ovary. *Cancer* 2011;117: 2096-103, PMID: 21120914.
- 95) **\*Zheng W**, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. *Am J Surg Pathol*. 2011, 35: 1-14.

Curriculum Vitae---Wenxin Zheng, M.D.

- 96) Abushahin N, Zhang T, Chiang S, Zhang X, Hatch K, **Zheng W\***. Serous endometrial intraepithelial carcinoma arising in adenomyosis: report of 5 cases. *Intl J Gynecol Pathol*, 2011, 30, 271-281. PMID: 21464726
- 97) Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, **Zheng W\***. Nrf2 expression in endometrial serous carcinomas and its precancers. *Int J Clin Exp Pathol*. 2010, 4:85-96. PMID: 21228930
- 98) Abushahin N, Fadare O, Liang XS, **Zheng W\***. Endometrial clear cell carcinoma: an update on recent concepts. *Pathology Case Reviews* 2011, 16: 108-114.
- 99) Jia L, Yi XF, Zhang ZB, Zhuang ZP, Li J, Chambers CK, Kong BH and **Zheng W\***. Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis. *Neoplasma* 2011, 58 (2): 104-109.
- 100) Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B\*, **Zheng W\***. Tubal origin of “ovarian” low-grade serous carcinoma. *Mod Pathol* 2011; 24: 1488-99.
- 101) Guo DH, **Zheng W**, Seng Y, Pang SJ. New insights for ovarian serous carcinomas. *J Diag Pathol*, 2011, 18: 308-310. (doi: 10 . 3969 /j . issn . 1007-8096 . 2011 . 04 . 026)
- 102) He L, Li L, Zhang TG, Zhang Y, Qiao YB, Cui BX, Jiang J, Wang B, Yang XS, Zhang YZ, **Zheng W**, Kong BH. Application of pathological diagnosis by rapid paraffin sections for biopsy in the diagnosis and treatment of cervical diseases. *Chin J Obstet Gynecol* 2011; 46: 516-20.
- 103) Wang F, Zhang YZ, Li L, Zhang TG, Kong BH, **Zheng W**. Clinical value of small cervical biopsy forceps for cervical lesions under colposcopy. *The Journal of Practical Obstetrics and Gynecology*, 2011, 27: 616-8. (doi: 10 . 3969 /j . issn . 1003-6946 . 2011-08-616-03)
- 104) Zhang X, Jia L, Kong BH, **Zheng W\***. Model for endometrial serous carcinogenesis. *Chin J Obstet Gynecol* 2011, 46: 472-475.
- 105) Kong BH, Zheng W. A proposed model of ovarian tumorigenesis and a new theory on the origin of ovarian cancer. *Chin J Obstet Gynecol* 2011, 46: 721-723.
- 106) Li J, Wang LJ, Xiang L, Kong BH, **Zheng W\***. Dualistic model of ovarian epithelial carcinogenesis and cell origin. *Chin J Obstet Gynecol* 2011, 46: 792-795.
- 107) Xiang L, Li J, Wang LJ, **Zheng W**, Kong BH. Origin of ovarian epithelial inclusions and its relationships with the development of low-grade serous carcinoma. *Chin J Obstet Gynecol* 2011, 46: 729-735.
- 108) Guo DH, **Zheng W**, Seng Y, Pang SJ. Insights of ovarian serous cancers. *J Diag Pathol*, 2011, 18: 308-310.

Curriculum Vitae---Wenxin Zheng, M.D.

- 109) Liu CR, **Zheng W**. Advances in origin and pathogenesis of epithelial ovarian cancer. *Chin J Pathol* 2011, 40: 569-72. PMID: 22169654
- 110) Pang SJ, **Zheng W**, Guo DH. Recent advances of pelvic serous carcinoma and tubal diseases. *J Clin Exp Pathol* 2012, 28: 801-803.
- 111) Guo DH, Pang SJ, Li J, **Zheng W**. Advances of tubal serous cancer. *Chin J Pathol* 2012, 41, 7: 490-493.
- 112) Li J, Fadare O, Xiang L, Kong BH, **Zheng W\***. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. *Journal of Hematology & Oncology* 2012, 5:8 [Epub ahead of print]
- 113) **Zheng W\***, Fadare O. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. *Int J Clin Exp Pathol* 2012;5(3):182-186. PMID: 22558471
- 114) Fadare O, **Zheng W\***. Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. *Am J Cancer Res.* 2012; 2: 335-9. PMID: 22679564
- 115) Unger W, Tang Q, Summers D, and **Zheng W\***. Collision Primary Tumor of the Endometrium: Large Cell Neuroendocrine Carcinoma and Endometrioid Adenocarcinoma. *Journal of Cancer Research Updates*, 2012, 1, 1-5.
- 116) Xiang L, **Zheng W\***, Kong B. Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology. *Gynecol Oncol*, 2012; 127(3):595-600
- 117) Zhang TG, **Zheng W**. Conceptual issues and diagnostic updates on endometrial serous carcinoma and its precursor. *Chinese Pathology Journal*, 2012, 41:724-6.
- 118) Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V. The Clinicopathologic Significance of p53 and BAF-250a (ARID1A) Expression in Clear Cell Carcinoma of the Endometrium. *Modern Pathol*, 2013, 26(8):1101-10.
- 119) Ning Y, Wang Y, Wang Y, Zheng W. Lynch Syndrome related endometrial cancer: Current status and future perspectives. *Chin J Pathol* 2013, 8, 1-4.
- 120) Fadare O, **Zheng W**, Crispens MA, Jones HW, Khabele D, Gwin K, Liang SX, Mohammed K, Parkash V, Desouki MM, Hecht JL. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: comprehensive analysis of 50 rigorously classified cases. *Am J Cancer Res.* 2013;3(1):70-95.
- 121) Ning Y, Kong F, Cragun JM, **Zheng W\***. Struma ovarii simulating ovarian sertoli cell tumor: a case report with literature review. *Int J Clin Exp Pathol.* 2013;6(3):516-20.

Curriculum Vitae---Wenxin Zheng, M.D.

- 122) Fadare O, Liang SX, Crispens MA, Jones HW, Khabele D, Gwin K, **Zheng W**, Mohammed K, Parkash V, Hecht JL, Desouki MM. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. *Human Pathol*, 2013 Aug;44(8):1508-15. doi: 10.1016/j.humpath.2012.12.003. Epub 2013 Mar 1.
- 123) Wang Y, Wang Y, Li J, Cragun JM, Hatch K, Chambers SK, **Zheng W\***. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. *J Hematol Oncol*. 2013 Mar 25;6(1):22. [Epub ahead of print]
- 124) Wang LJ, Yuan Z, Jia L, Hao CY, Zhang Y, **Zheng W**, Kong BH. The successful rate of endocervical curettage mainly relies on the holding materials for the tissue samples. *Chin J Obstet Gynecol*, 2013, 48, 1: 1-2
- 125) Li J, Ning Y, Abushahin N, Wang Y, Wang Y, Yuan Y, Cragun JM, Chambers SK, Hatch K, Kong B, Zheng W. Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. *Gynecol Oncol*, 2013 Sep 20. doi:pii: S0090-8258(13)01192-X. 10.1016/j.ygyno.2013.09.018. [Epub ahead of print]
- 126) Abushahin A, Zhao RJ, Jia L, **Zheng W\***. Endometrial precancers: from concept to practice. *Diagnostic Histopathol*, 2013, 19, 256-266.
- 127) Guo DH, **Zheng W**. Pathologic features of BRCA associated ovarian cancer. *Chin J Pathol*, 2013, 42 (12): 846-850.
- 128) Guo DH, **Zheng W**. Recent advances of ovarian epithelial cancer in its definition, subtypes, and pathologic diagnostic features. *Chin J Pathol*, 2013, 42 (9), 624-628.
- 129) Wang Y, Wang Y, Li J, Yuan Z, Yuan B, Zhang T, Cragun JM, Kong B, **Zheng W\***. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. *J Hematol Oncol*. 2013 Aug 19;6(1):60. doi: 10.1186/1756-8722-6-60.
- 130) Chambers SK, Zheng W, Adashi EY, Hatch KD, Kong B, Plaxe S, Silver RM: Launch of American Journal of Clinical and Experimental Obstetrics and Gynecology. *Am J Clin Exp Obstet Gynecol* 2013;1(1), the first page.
- 131) Han LM, Wei L, Ferguson DC, Chambers SK, Fadare O, Wang Y, **Zheng W\***: From endometrial glandular dysplasia to endometrial serous carcinoma: insights into underlying biological aspects. *Am J Clin Exp Obstet Gynecol* 2013;1(1):1-16.
- 132) Chen C, Li J, Yao G, Chambers SK, **Zheng W**: Tubal origin of ovarian low-grade serous carcinoma. *Am J Clin Exp Obstet Gynecol* 2013;1(1):31-36.
- 133) Yuan Z, Wang Y, Cragun JM, Chambers SK, **Zheng W\***: Cell origin of endometriosis: contribution by the fallopian tube epithelium. *Am J Clin Exp Obstet Gynecol* 2013;1:37-42.

Curriculum Vitae---Wenxin Zheng, M.D.

- 134) Wang Y, Wang Y, **Zheng W\***. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. *Int J Clin Exp Pathol*. 2013, 6:2121-8.
- 135) Guo DH, Shen DH, **Zheng W**. Endometrial cancer: how to make your pathology report correctly? *Chin J Pathol*, 2014, 43 (2): xx-xx.
- 136) Gruessner C, Gruessner A, Glaser K, AbuShahin N, Laughren C, **Zheng W**, Chambers SK. Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma. *Am J Cancer Res* 2014; 4: 61-72.
- 137) Yuan Z, Wang L, Wang Y, Zhang T, Li L, Cragun JM, Chambers SK, Kong B, **Zheng W\***. Tubal origin of ovarian endometriosis. *Mod Pathol* 2014, 2014 Jan 3. doi: 10.1038/modpathol.2013.245. [Epub ahead of print] PMID: 24390223
- 138) Fadare O, Desouki MM, Gwin K, Hanley KZ, Jarboe EA, Liang SX, Quick CM, **Zheng W**, Parkash V, Hecht JL. Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility. *Am J Surg Pathol*. 2014, 38: 189-196.
- 139) Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, and **Zheng W\***. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. *Mod Pathol*, 2014 Jun 13. doi: 10.1038/modpathol.2014.76. [Epub ahead of print]
- 140) Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer JB, Azodi M, **Zheng W**, Chambers SK. Flutamide and biomarkers of risk for ovarian cancer: pre-clinical and clinical study. *Cancer Prev Res (Phila)*. 2014 Jun 20. pii: canprevres. 0408.2013. [Epub ahead of print]
- 141) Wang Y, Li L, Wang Y, Yuan Z, Zhang W, Hatch DK, and **Zheng W\***. IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. *J Exp Clin Cancer Res*, 2014, 33(1):60. [Epub ahead of print] PMID: 25038792
- 142) Wang Y, Wang Y, Li D, Li L, Zhang W, Yao G, Jiang Z, and **Zheng W\***. IMP3 signatures of fallopian tube: a risk for pelvic serous cancers. *J Hematol Oncol*. 2014 Jul 12;7(1):49. [Epub ahead of print] PMID: 25014991
- 143)

#### **Editorials, Reviews, Chapters, Books:**

- 1). Bellve AR, **Zheng W**. Pleiotypic actions of the seminiferous growth factor. In “Molecular mechanisms in cellular growth and differentiation”. Eds: Bellve AR and Vogel HJ, Academic Press, Inc., New York. 1991, pp 187-205.



Curriculum Vitae---Wenxin Zheng, M.D.

- 2). Bellve AR, **Zheng W**, Martinova YS. Recovery, capacitation, acrosome reaction, and fractionation of sperm. In “A guild to techniques in Mouse Development”. Eds: Wassarman PM and DeThamphilis M. *Methods Enzymol* 1993, 225, 113-136.
- 3). Schwartz PE, Chu MC, **Zheng W**, Mor G. Endometrial stromal tumors – are they hormonally sensitive? In Hormone Replacement Therapy and Cancer. The Current Status of Research and Practice. Edited by A.R. Genazzani, The Parthenon Publishing Group, London, 2002, pp148-154.
- 4) **Zheng W**. Chapter 24, Vulva and Vagina . In Essentials of Anatomic Pathology, 2<sup>nd</sup> Edition. Edited by Cheng L and Boswick D, 2005, pp 24-1 to 24-18.
- 5). **Zheng W**. Eosinophilic Dysplasia of the cervix, which are the invasive and cytologic counterparts? Am J Surg Pathol, 2005, 29: 837-838.
- 6) **Zheng W** and Robboy Stanley. Chapter 9 Cervical squamous cell carcinoma. In Robboy’s Pathology of the female reproductive tract. Edited by Robboy SJ et al, 2<sup>nd</sup> edition.
- 7) **Zheng W** and Robboy Stanley. Chapter 19 Fallopian tube. In Robboy’s Pathology of the female reproductive tract. Edited by Robboy SJ et al, 2<sup>nd</sup> edition.
- 8) **Zheng W (Chief editor)**, Shen D, Guo D. Pathology of Obstetrics and Gynecology. 2013, the 1<sup>st</sup> edition, Beijing, Science Press.

#### Case Reports:

- 1). **Zheng W**, Yang G, Caputo T, Godwin T, Zuna R. Mucinous adenocarcinoma of the endometrium with intestinal differentiation: A case report. Hum Pathol, 26: 1385-1388, 1995
- 2). Magid MS, Godwin TA, **Zheng W**. Hepatic heterotopias in the jejunum: A case study over time showing progressive degenerative changes. Pediat Pathol Lab Med 1997, 17: 663-670.
- 3). Fadare O, **Zheng W**. A 44-Year-Old Woman with Menometrorrhagia: Myxoid and Fibrous Low grade Endometrial Stromal Sarcoma. Arch Pathol Lab Med, 2005, 129: 195-198.
- 4) Liang SX, Patel K, Pearl M, Liu J, **Zheng W**, Tornos K. Sertoliform Endometrioid Carcinoma of the Endometrium With Dual Immunophenotypes for Epithelial Membrane Antigen and Inhibin: Case Report and Literature Review. Intl J Gynecol Pathol, 2007, 26: 291-297.
- 5) Ning Y, Kong F, Cragun JM, **Zheng W**. Struma ovarii simulating ovarian sertoli cell tumor: a case report with literature review. Int J Clin Exp Pathol. 2013; 6(3):516-20.

#### Abstracts

More than 100 abstracts, which were mainly presented in USCAP meetings, are not listed here.

#### Non Peer Review

- 1). **Zheng W**. Pathology advances prior to other medical specialties. Journal of American Chinese Association of Physicians. May 2005.

Curriculum Vitae---Wenxin Zheng, M.D.

### Book Reviews:

**Zheng W**, Parkash V. Book Review: Atlas of Tumor Pathology: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tubes, and Broad Ligament. Third Series (Fascicle 23) By Robert E. Scully, Robert H. Young and Philip B. Clement, 1998 AFIP. Am J Surg Pathol, 2001, 26, 277-278.

### Books:

**Zheng W**, Editor in Chief, Shen DH and Guo DH, Co-editors: Obstetrics and Gynecologic Pathology (in Chinese), Science Press, Beijing, China, 2013, first edition.

### Work in Progress

1. **Zheng W** et al., Endometrial serous carcinoma with a tubuloglandular pattern: an under recognized form of aggressive endometrial cancer.
2. Yi XF and **Zheng W** et al., In vivo evidence of ovarian stromal-epithelial interaction: a descriptive study by morphologic examination of ovarian epithelial inclusions or endosalpingiosis.
3. **Zheng W** et al., A differential role of FSH and LH in the ovarian epithelial carcinogenesis.
4. **Zheng W** et al., FSH up-regulated proteins are mostly cell cycle promoters: evidence supporting FSH as a growth promoter in ovarian tumorigenesis.
5. **Zheng W** et al., Imbalance of gonadotropins and sex steroid hormones is critical in the process of ovarian epithelial tumorigenesis.
6. **Zheng W** et al., Biomarkers to predict the prognosis and therapeutic choices for endometrial cancers.

